Rolapitant eases nausea in cancer patients, Tesaro soars
This article was originally published in Scrip
Executive Summary
Tesaro's stock closed 21% higher on 12 May after the company said rolapitant met all primary and secondary endpoints in a Phase III clinical trial for cancer patients with chemotherapy-induced nausea and vomiting (CINV) with a potentially differentiating reduction in nausea.